Education
About Us
Working with TipRanks
Follow Us
Omeros Corp (OMER)
NASDAQ:OMER
OMER Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.95 - $13.60
Previous CloseN/A
Volume193.12K
Average Volume (3M)962.86K
Market Cap
$285.83M
Enterprise Value$529.02M
Total Cash (Recent Filing)$28.74M
Total Debt (Recent Filing)$184.33M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 05, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding68,055,824
10 Day Avg. Volume947,400
30 Day Avg. Volume962,858
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.85
Enterprise Value/Revenue1.28K
Enterprise Value/Gross Profit-728.68
Enterprise Value/Ebitda-4.18
Forecast
1Y Price Target
$9.00Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company is in discussions for a potential asset acquisition/licensing agreement that could provide an upfront payment of up to $150MM-$200MM.
Market ExpansionNarsoplimab will be approved in the U.S. and Europe, and will create significant value for OMER, given the company has been successful in commercializing products in the past.
Product ApprovalNarsoplimab demonstrates a differentiated clinical profile and reinforces its potential to become the first approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA).
Bears Say
Financial ConcernsThere is an urgent financial overhang that the company needs to address, indicating financial instability.
Market UncertaintyThere is an uncertain path forward for the company, contributing to the maintenance of a Hold rating.
Regulatory ChallengesThere is skepticism about FDA approval of narsoplimab due to the limited clinical dataset and lack of new clinical data.
Omeros News
OMER FAQ
What was Omeros Corp’s price range in the past 12 months?
Omeros Corp lowest stock price was $2.95 and its highest was $13.60 in the past 12 months.
What is Omeros Corp’s market cap?
Omeros Corp’s market cap is $285.83M.
When is Omeros Corp’s upcoming earnings report date?
Omeros Corp’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.
How were Omeros Corp’s earnings last quarter?
Omeros Corp released its earnings results on Aug 14, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.503 by $0.073.
Is Omeros Corp overvalued?
According to Wall Street analysts Omeros Corp’s price is currently Undervalued.
Does Omeros Corp pay dividends?
Omeros Corp does not currently pay dividends.
What is Omeros Corp’s EPS estimate?
Omeros Corp’s EPS estimate is -0.45.
How many shares outstanding does Omeros Corp have?
Omeros Corp has 68,055,824 shares outstanding.
What happened to Omeros Corp’s price movement after its last earnings report?
Omeros Corp reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.503. Following the earnings report the stock price went up 7.039%.
Which hedge fund is a major shareholder of Omeros Corp?
Currently, no hedge funds are holding shares in OMER
Omeros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (105.48% Upside)
$9.00 (105.48% Upside)
Blogger Sentiment
Neutral
OMER Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 61.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.96%
12-Months-Change
Fundamentals
Return on Equity
87.26%
Trailing 12-Months
Asset Growth
-43.71%
Trailing 12-Months
Company Description
Omeros Corp
Omeros Corporation (OMER) is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for various medical conditions. The company operates primarily in the field of inflammation, coagulopathies, and central nervous system disorders. Omeros' lead product, Omidria, is used in cataract and lens replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain. Additionally, the company is engaged in multiple clinical-stage development programs targeting conditions such as complement-mediated diseases and addiction.
OMER Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a mostly positive outlook, with significant progress in financial restructuring and regulatory advancements for narsoplimab, despite some delays and decreased income from certain operations.View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
$9.00
▲(105.48% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Abeona Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.90%
Insiders
7.21% Mutual Funds
8.93% Other Institutional Investors
72.00% Public Companies and
Individual Investors